Last updated 21 days ago
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
360 patients around the world
Available in Mexico, United States
Eli Lilly and Company
5Research sites
360Patients around the world
This study is for people with
Obesity
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Have a body mass index (BMI) of ≥30 kilogram/square meter (kg/m2) and ≤40 kg/m2.Willing to learn how to self-inject study intervention (visually impaired persons who are not able to perform the injections must have the assistance of a sighted individual trained to inject the study intervention; persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject the study intervention).Male or female contraceptive use by participant should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Have a history of diabetes mellitus, including Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM), history of ketoacidosis, or hyperosmolar state/coma.Have a self-reported change (increase or decrease) in body weight >5 kilogram (kg) within 3 months prior to screening.Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2.Have acute or chronic hepatitis.Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years.
Sites
Centro de Investigación en Artritis y Osteoporosis
Clínicos Asociados BOCM S.C.
UBAM Unidad Biomédica Avanzada Monterrey
Medical Care & Research SA de CV
Investigación en Salud y Metabolismo S.C
SponsorEli Lilly and Company
Conditions
Obesity
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06373146
